openPR Logo
Press release

Anticoagulant Reversal Drugs Market is predicted to grow at a staggering CAGR of 16% from 2020-2026

04-14-2021 03:59 PM CET | Health & Medicine

Press release from: Fact.MR

Anticoagulant Reversal Drugs Market

Anticoagulant Reversal Drugs Market

Increasing preference for minimally-invasive surgeries along with rise in the number of ambulatory surgical procedures, inadvertently creates a highly conducive environment for the growth of the anticoagulant reversal drugs market. Another significant boost to the sales of anticoagulant reversal drugs can be attributed to their new technology add-on payment (NTAP) status, as designated by the U.S. Following this, patients are accessing these drugs along with Medicare/Medicaid plans in hospital settings, which is projected to generate significant sales from hospital pharmacies.

Given the relevance of these dynamics, a comprehensive study published by Fact.MR foresees that, the global anticoagulant reversal drugs market will expand at a staggering CAGR of ~16% during the forecast period (2020-2026).

To get in-depth information view the report @
https://www.factmr.com/report/4338/anticoagulant-reversal-drugs-market

Key Highlights of Anticoagulant Reversal Drugs Market Study

Launch of novel drugs with relatively high efficiency and better recovery times could overshadow the popularity of conventional drugs such as prothrombin complex concentrates and vitamin K.
High prices of patented drugs could impede the penetration of anticoagulant reversal drugs, especially in developing economies. In developed countries of North America and Europe, favourable reimbursement scenarios are increasing patients’ reliance on effective anticoagulant reversal drugs.
The designation of Andexxa as an orphan drug by the U.S. Food and Drug Administration is anticipated to influence the infiltration rate of this drug during the forecast period (2020-2026). The fast-track approval of Andexxa will meet unmet clinical needs, thereby promising lucrative opportunities for players in the anticoagulant reversal drugs market.

Manufacturers in the anticoagulant reversal drugs market are capitalizing on profitable opportunities present in developed and developing countries of Asia Pacific to target a relatively wide patient pool and enhance their market exposure. For instance, a key player—Portola Pharmaceuticals—entered into a licensing partnership with Pfizer and BMS. According to the contract, both these partner companies will have commercial rights of Andexxa in Japan.

For more insights into the Market, Request a Sample of this Report @https://www.factmr.com/connectus/sample?flag=S&rep_id=4338

Hospital pharmacies are projected to generate the highest sales in the anticoagulant reversal drugs market during the forecast period. Growing number of patient admissions in hospitals and the need to control bleeding during surgeries are projected to create enormous sales opportunities for hospital pharmacies.

“Collectively, Idarucizumab and Andexxa hold a majority share in the anticoagulant reversal drugs market, owing to their utmost efficiency. However, the ‘orphan drug’ status of Andexxa could give it an edge over other drugs”, foresees a seasoned analyst at Fact.MR.

Access Research Methodology Prepared By Experts @https://www.factmr.com/connectus/sample?flag=RM&rep_id=4338

Market Majors Focus on Branded Drugs, Regional Players Produce Generic Drugs

Boehringer Ingelheim GmbH, CSL Limited, and Portola Pharmaceuticals, Inc. dominate the anticoagulant reversal drug market. These players rely on research & development activities to introduce a range of effective drugs to enrich their portfolio. Expansion of production facilities, in turn, remains one of the top agendas of these players in the anticoagulant reversal drugs market. For example, market leader—Boehringer Ingelheim GmbH—operates through 29 production facilities located across nine countries, which are categorized into Biopharmaceuticals, Animal Health, and Human Pharmaceuticals. However, these leading players produce drugs in only one drug class, which is generally Prothrombin Complex Concentrate.

In stark contrast to THE strategies adopted by leading players in the anticoagulant reversal drugs market, regional and local players strive to consolidate their market position by increasing investments towards THE production of generic versions of branded drugs. For instance, Amneal Pharmaceutical Inc. announced the launch of Phytonadione tablets, a generic version of Mephyton.

To get in-depth insights on the regional landscape of the market, ask an analyst here @https://www.factmr.com/connectus/sample?flag=AE&rep_id=4338

Find More Valuable Insights on Anticoagulant Reversal Drugs Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global anticoagulant reversal drugs market, presenting historical demand data (2016-2019), and forecast statistics for the period of 2020-2026. The study divulges compelling insights on the anticoagulant reversal drugs market on the basis of Product (Prothrombin Complex Concentrates, Andexxa, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and Others) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), across five major regions.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email : sales@factmr.com
Website : https://www.factmr.com
Research Insight: https://www.factmr.com/report/4338/anticoagulant-reversal-drugs-market
Content Source: https://www.factmr.com/media-release/1166/global-anticoagulant-reversal-drugs-market

About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions.
We have offices in US and Dublin, whereas our global headquarter is in Dubai.While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise.
Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.
Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anticoagulant Reversal Drugs Market is predicted to grow at a staggering CAGR of 16% from 2020-2026 here

News-ID: 2270221 • Views:

More Releases from Fact.MR

Ice Skating Equipment Market worth is poised to reach US$ 1478 Billion in 2033
03-28-2024 | Sports
Fact.MR
Ice Skating Equipment Market worth is poised to reach US$ 1478 Billion in 2033
The global ice skating equipment market garnered a market value of US$ 6.87 Billion in 2022 and is expected to accumulate a market value of US$ 16.26 Billion by registering a CAGR of 9% in the forecast period 2023-2033. Ice skating is a popular activity observed in numerous snow-clad regions around the world, serving various purposes including exercise, leisure, and excitement. This recreational pursuit can occur in specially prepared ice arenas
Global Barcode Software Market is predicted to be valued at US$ 1.4 Billion by 2032
Global Barcode Software Market is predicted to be valued at US$ 1.4 Billion by 2 …
The barcode software market is predicted to grow at a moderate CAGR of 6.3% over the forecast period of 2022 to 2032. The barcode software market is estimated to achieve a net worth of about US$ 1.4 Billion in the year 2032, improving from US$ 694.9 Million recorded in 2021. For more insights into the Market, Get A Sample of this Report! https://www.factmr.com/connectus/sample?flag=S&rep_id=7368 The barcode software market emerges as a crucial enabler of
Hardware Acceleration is forecasted to accelerate at a commendable CAGR of 51% from 2023 to 2033
Hardware Acceleration is forecasted to accelerate at a commendable CAGR of 51% f …
The global hardware acceleration market stands at US$ 2.87 billion in 2023. Worldwide demand for hardware acceleration technology is projected to skyrocket at a CAGR of 51% and reach a market value of US$ 177 billion by 2033. Hardware acceleration refers to the use of specialized hardware components to perform specific tasks more efficiently than general-purpose processors. This technology has gained significant traction across various industries due to its ability to
03-28-2024 | Food & Beverage
Fact.MR
Marine Collagen Ingredients Market value is projected to reach US$ 2,320.6 milli …
According to Fact.MR analysis, the marine collagen ingredients market is poised for steady growth in the coming years. The market's overall value is anticipated to exceed US$ 2,320.6 million by the year 2033, a significant increase from US$ 1,076.8 million recorded in 2023. Projections indicate a robust compound annual growth rate (CAGR) of 8.0% during the assessment period spanning from 2023 to 2033. Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=8704 In recent

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug